GlaxoSmithKline Pharmaceuticals Ltd

GLAXO
Health CarePharmaceuticals
MidcapWith a market cap of ₹28,315 cr, stock is ranked 172
Low RiskStock is 1.58x as volatile as Nifty
1,691.9520.50 (+1.23%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹28,315 cr, stock is ranked 172
Low RiskStock is 1.58x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
80.03
PB RatioPB Ratio
19.12
Dividend YieldDiv. Yield
1.77%
Sector PESector PE
38.42
Sector PBSector PB
5.12
Sector Div YldSctr Div Yld
0.67%

Forecast & RatingsDetailed Forecast 

43%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.

Brands

Glaxosmithkline Pharma

Pharmaceutical company

Brands

Glaxosmithkline Pharma

Pharmaceutical company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

20182019202020212.943.283.853.350.350.450.090.36
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Spurt in Volume 
Announced OnNov 26, 2021

Significant increase in volume has been observed in GlaxoSmithKline Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. GlaxoSmithKline Pharmaceuticals Limited has submitted their response. | Download

Significant increase in volume has been observed in GlaxoSmithKline Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. GlaxoSmithKline Pharmaceuticals Limited has submitted their response. | Download

Change in Director(s) 
Announced OnNov 25, 2021

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company. | Download

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company. | Download

Cash Dividend 
Ex. DateJul 19, 2021

Final • Div/Share: ₹ 30

See all events